2.50
Hdl Handle:
http://hdl.handle.net/10541/94755
Title:
Growth hormone therapy and malignancy.
Authors:
Shalet, Stephen M; Brennan, Bernadette M; Reddingius, R E
Abstract:
The possibility that human growth hormone (GH) replacement therapy might either increase the risk of cancer recurrence in a child who has previously been treated for a brain tumour or leukaemia, or induce de novo cancer, has worried paediatricians for a number of years. Concern arises from animal experiments, the association of acromegaly with malignancy, and the Japanese experience of a cluster of de novo leukaemia cases in children treated with GH. It is reassuring that so far the results from single centre studies and from the pharmaceutical industry surveillance programmes have shown no evidence of an increased risk of malignancy, recurrent or de novo. The confidence intervals, however, are wide and the scientific nature of these studies is flawed as there has never been a prospective randomized study of GH replacement in children with radiation-induced GH deficiency. For clinical reasons, such a study is unlikely to be performed and therefore surveillance must be maintained at a very high level.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, UK.
Citation:
Growth hormone therapy and malignancy. 1997, 48 Suppl 4:29-32 Horm. Res.
Journal:
Hormone Research
Issue Date:
1997
URI:
http://hdl.handle.net/10541/94755
DOI:
10.1159/000191309
PubMed ID:
9350443
Type:
Article
Language:
en
ISSN:
0301-0163
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorShalet, Stephen Men
dc.contributor.authorBrennan, Bernadette Men
dc.contributor.authorReddingius, R Een
dc.date.accessioned2010-03-23T16:50:57Z-
dc.date.available2010-03-23T16:50:57Z-
dc.date.issued1997-
dc.identifier.citationGrowth hormone therapy and malignancy. 1997, 48 Suppl 4:29-32 Horm. Res.en
dc.identifier.issn0301-0163-
dc.identifier.pmid9350443-
dc.identifier.doi10.1159/000191309-
dc.identifier.urihttp://hdl.handle.net/10541/94755-
dc.description.abstractThe possibility that human growth hormone (GH) replacement therapy might either increase the risk of cancer recurrence in a child who has previously been treated for a brain tumour or leukaemia, or induce de novo cancer, has worried paediatricians for a number of years. Concern arises from animal experiments, the association of acromegaly with malignancy, and the Japanese experience of a cluster of de novo leukaemia cases in children treated with GH. It is reassuring that so far the results from single centre studies and from the pharmaceutical industry surveillance programmes have shown no evidence of an increased risk of malignancy, recurrent or de novo. The confidence intervals, however, are wide and the scientific nature of these studies is flawed as there has never been a prospective randomized study of GH replacement in children with radiation-induced GH deficiency. For clinical reasons, such a study is unlikely to be performed and therefore surveillance must be maintained at a very high level.en
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshAcromegaly-
dc.subject.meshChild-
dc.subject.meshCluster Analysis-
dc.subject.meshGrowth Disorders-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshJapan-
dc.subject.meshLeukemia-
dc.subject.meshNeoplasms-
dc.subject.meshRadiation Injuries-
dc.subject.meshRecurrence-
dc.titleGrowth hormone therapy and malignancy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalHormone Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.